GFG Capital’s Edwards Lifesciences EW Stock Holding History

GFG Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-57	Closed	-$4.46K	–	150
2025 Q2	$4.46K	Buy	+57	New	+$4.25K	﹤0.01%	271

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

GFG Capital's EW Position: Q3 2025 in Review

GFG Capital sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 57 shares — an estimated $4.46K sold.

GFG Capital first reported a position in EW in Q2 2025 and held it in 1 quarter. The position peaked at $4.46K in Q2 2025. 1,253 funds tracked by Wall St. Rank hold EW as of Q3 2025.

GFG Capital reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
GFG Capital sold 57 Edwards Lifesciences shares in Q3 2025, an estimated $4.46K.
GFG Capital first reported a position in Edwards Lifesciences in Q2 2025 and held it in 1 quarter.
GFG Capital's Edwards Lifesciences position peaked at $4.46K in Q2 2025.
1,253 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.